This week is a special two-part episode focusing on last week’s controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer’s drug. In these episodes, I talk with two Alzheimer’s experts with vastly different viewpoints on the news. First up: Dennis J. Selkoe, a physician and scientist whose research is at the core of how Aduhelm works.

Episode 19, Part 1: An original believer on the aducanumab decision

First, we discuss the CDC's about-face on mask wearing, the debate over vaccine booster shots, and the slow but steady race to develop pills for Covid-19. Then, STAT's Kate Sheridan joins us to discuss a setback in the field of microbiomics and the mounting skepticism over whether tinkering with gut bacteria can eventually treat a host of diseases. We also break down the latest fallout from the FDA's approval of Aduhelm, the sorry state of biotech stocks, and an in-development feature film about CRISPR.

Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Episode 171: The quest for a Covid pill, a microbiome gut-check, & CRISPR on the big screen

STAT

Related tracks